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Abstract
Background: Sevelamer is an alternative to calcium carbonate for the treatment of hyperphosphatemia among
non-dialysis dependent patients with chronic kidney disease (CKD). Although some studies show that it may
reduce mortality and delay the onset of dialysis when compared to calcium carbonate, it is also significantly
more expensive. Prior studies looking at the incremental cost-effectiveness of sevelamer versus calcium carbonate
in pre-dialysis patients are based on data from a single clinical trial. The goal of our study is to use a wider range
of clinical data to achieve a more contemporary and robust cost-effectiveness analysis.
Methods: We used a Markov model to estimate the lifetime costs and quality-adjusted life years (QALYs) gained
for treatment with sevelamer versus calcium carbonate. The model simulated transitions among three health states
(CKD not requiring dialysis, end-stage renal disease, and death). Data on transition probabilities and utilities were
obtained from the published literature. Costs were calculated from a third party payer perspective and included
medication, hospitalization, and dialysis. Sensitivity analyses were also run to encompass a wide range of assumptions
about the dose, costs, and effectiveness of sevelamer.
Results: Over a lifetime, the average cost per patient treated with sevelamer is S$180,724. The estimated cost for
patients treated with calcium carbonate is S$152,988. A patient treated with sevelamer gains, on average, 6.34
QALYs relative to no treatment, whereas a patient taking calcium carbonate gains 5.81 QALYs. Therefore, sevelamer
produces an incremental cost-effectiveness ratio (ICER) of S$51,756 per QALY gained relative to calcium carbonate.
Conclusion: Based on established benchmarks for cost-effectiveness, sevelamer is cost effective relative to
calcium carbonate for the treatment of hyperphosphatemia among patients with chronic kidney disease initially
not on dialysis.
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Background
Chronic kidney disease (CKD), defined as having two
consecutive eGFR values <60 mL/min/1.73 m2 separated
by at least 90 days, is on the rise in Singapore. The num-
ber of CKD patients increased more than 2-fold between
2007 and 2011, from 4734 to 10,245 cases. CKD is now
the 9th leading cause of death in Singapore. It also
imposes significant costs on the health care system. For
example, more than 1000 CKD patients are now receiv-
ing dialysis, often at highly subsidized rates [1].
One of the primary causes of increased healthcare
utilization and premature mortality among CKD pa-
tients is hyperphosphatemia. This occurs when serum
phosphate levels are abnormally high, defined to be
greater than 4.6 mg/dL in CKD patients and greater
than 5.5 mg/dL in dialysis patients, according to the
KDOQI guidelines [2]. Healthy individuals are able to
rid the body of excess phosphate partly through urinary
excretion. However, as renal function worsens, this
mechanism is significantly impaired. This leads to in-
creased vascular calcification and greater risk of cardio-
vascular events. Numerous studies have shown a dose/
response relationship between hyperphosphatemia in
CKD and increased cardiovascular diseases (CVD) and
all-cause mortality [3, 4]. Standard treatment for hyper-
phosphatemia, in addition to consumption of a low
phosphate diet, typically includes administration of
calcium-based binders and non-calcium based binders
that are able to block absorption of ingested phosphate.
More recently, the prescription medication, sevelamer
has been used as a non-calcium-based alternative. Stud-
ies have shown that sevelamer is at least as effective as
calcium binders in reducing serum phosphate levels
while causing less vascular calcification [5]. A recent
randomized controlled trial of CKD patients not on
dialysis [6] found that sevelamer delays progression to
dialysis, and a meta-analysis concluded that sevelamer
leads to improved survival outcomes [7].
Despite the health benefits, sevelamer is seven times
as expensive as calcium carbonate in Singapore. This
raises the question of whether sevelamer is a good use of
scarce healthcare resources. To our knowledge, only two
studies have looked at the incremental cost-effectiveness
of sevelamer versus calcium carbonate in CKD patients;
both relied on the clinical data from the INDEPEND-
ENT trial [6]. The first study by Thompson et al. [8]
used a Markov model with three health states (non-dia-
lysis CKD, end-stage renal disease and all-cause death)
to simulate the lifetime cost utility of sevelamer versus
calcium carbonate for pre-dialysis CKD patients in the
UK. They found that sevelamer has an incremental cost
effectiveness ratio (ICER) of £23,878 (S$49,000) per
QALY gained, which is considered cost-effective using
the National Institute for Health and Care Excellence
(NICE) benchmark of £30,000 (S$61,000) per QALY
gained. However, Thompson et al. assumed a mortality
hazard ratio of sevelamer compared to calcium carbon-
ate of 0.45. This is well below the recent estimate from
the Jamal et al. 2013 meta-analysis, which reports a
mean hazard ratio of 0.88 [7]. Moreover, Thompson et
al. assumed a constant dose for sevelamer (2.184 g/day)
whereas CKD patients tend to increase to higher and
more expensive doses over time, and especially after
dialysis initiation. As a result of these assumptions,
their cost-effectiveness ratio may be overly optimistic.
The second study by Ruggeri et al. [9], also used an
overly optimistic mortality hazard for sevelamer and
limited the time-frame of analysis to three years, leav-
ing the question about long term cost effectiveness
unanswered.
Given the limitations of prior studies, the goal of this
study is to revisit the long term cost-effectiveness of
sevelamer relative to calcium carbonate. We create a
Markov model using a specific mortality hazard from
Jamal et al. and, consistent with current practice, specific
higher doses of sevelamer that increase for a given pa-
tient over time. To the extent possible, we tailor the
model for use in Singapore, the country of focus for this
effort, but it can easily be applied to other countries.
Methods
Model structure
We developed a cohort Markov decision model using
TreeAge Pro 2013 to simulate the ICER of sevelamer
among incident CKD patients who have not yet started
dialysis. The hypothetical cohort consisted of 1000 pa-
tients with mean age of 60. Age 60 corresponds to the
average age of a representative cohort of CKD patients
in Singapore [1]. As with Thompson et al., the Markov
model considered 3 health states: CKD with no dialysis,
end-stage renal disease, and all-cause mortality. Trans-
plant was not included in the model because the number
of transplants conducted in Singapore is very small (less
than 60 cases per year). In any period, a patient in the
‘CKD with no dialysis’ state could either stay dialysis-
free or transition to dialysis. Once dialysis is initiated,
the patient was assumed to continue with dialysis until
death, which may occur in any time period. Mortality
risks are time-dependent and differ between non-dialysis
CKD and end-stage renal disease patients. The base
model was run for multiple one-year cycles until all co-
hort members died (i.e., lifetime horizon). The Markov
decision tree for the two treatment drugs under com-
parison is presented in Fig. 1.
Model inputs
The cost input data is Singapore specific. Data for other
model inputs were obtained from the published literature
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and where possible, from studies that were specific to
Singaporean or Asian populations. Model inputs are sum-
marized in Table 1. No informed consent was needed as
only secondary data was used in the analysis.
Transition probabilities
Transition probabilities were obtained from published
studies and from our own calculations. The probabilities
for transitioning to dialysis in each cycle were obtained
from Di Iorio et al., which presents results of a three
year randomized controlled trial designed to test the
clinical effectiveness of sevelamer versus calcium car-
bonate for treatment of hyperphosphatemia among CKD
patients in Italy [6].
Although Di Iorio et al. also contains mortality transi-
tion probabilities, this data is only available for the
three-year duration of the clinical trial. Further, in an
erratum it was clarified that patients were right censored
(i.e., removed) from analysis when they entered dialy-
sis [10]. As a result, the mortality data from their
paper is not an accurate representation of the lifetime
mortality hazard. Therefore, we estimated mortality
transition probabilities based on data from the litera-
ture. To estimate mortality risks of non-dialysis CKD
patients, we used data on three parameters: (a) age-
specific mortality risks from Singapore life-tables [11],
(b) mortality hazard ratios for CKD patients relative to
non-CKD patients based on a large Taiwanese cohort
study [12], and (c) mortality hazard ratios for sevelamer
relative to calcium carbonate among CKD patients ob-
tained from a recent meta-analysis [7].
Specifically, we first inflated the age specific mortality
risks from the Singapore life tables by the hazard ratio
for CKD patients. These inflated mortality risks were
assumed to be the mortality risks for CKD patients
treated with calcium carbonate, which is currently stand-
ard treatment in Taiwan. We next calculated mortality
risks for those treated with sevelamer by multiplying the
mortality risks for CKD patients treated with calcium
carbonate by the sevelamer-specific hazard ratio from
the Jamal et al. study. For mortality risks for CKD pa-
tients on dialysis, we used age-specific mortality risks
from the US Renal Data System [13] as no similar data
was available for Singapore but adjusted them down by
25 %. This adjustment factor is based on Wong et al.
[14] showing that the mortality risk of Asian American
end-stage renal disease patients was 0.75 compared to
that of non-Asian American end-stage renal disease
patients. These mortality risks were then differentiated
between the two drugs using the same sevelamer-
specific hazard ratio as above.
Costs
Costs consist of three components: medication, dialysis,
and hospitalizations. Annual drug costs for sevelamer and
calcium carbonate were calculated as the product of the
market acquisition unit price for each drug times its dos-
age per day times 365 days per year. Data on the acquisi-
tion prices (S$1.41/g for sevelamer and S$0.192/g for
calcium carbonate) were provided by the manufacturer.
Dosage for each drug differs between non-dialysis CKD
and end-stage renal disease patients. For non-dialysis
CKD patients, constant doses of (2.184 g/day for sevela-
mer and 2.95 g/day for calcium carbonate) were assumed.
For end-stage renal disease patients, higher doses over
time are often required as the disease progresses. There-
fore, dosage of sevelamer for these patients was set to be
2.4 g/day in the first year, 4.8 g/day in years 2–4, 7.2 g/day
in years 5–7, and 9.6 g/day from year 8 onwards [15]. Due
to the lack of data on changes in dosage over time for pa-
tients on calcium carbonate and because of its very low
cost relative to sevelamer, we assumed a constant dose
(2.95 g/day).
Costs for dialysis were calculated as the weighted
average of the unsubsidized costs of haemodialysis and
peritoneal dialysis made public by the Singapore Minis-
try of Health. The weights were the proportions of
CKD patients in each dialysis modality (17.7 % for
Fig. 1 Markov decision tree
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Table 1 Model inputs
Variable name Base case Range Source
Markov basic parameters in the base case
Time horizon Lifetime (30 years) 2–40 years Assumed
Cycle length 1 year – Assumed
Discount rate 3.5 % – NICE, 2013
Transitional probabilities
Probability of dialysis initiation Age dependent Di Iorio et al. 2012 [6, 10]
Mortality risk for CKD patients without dialysis Age dependent Calculated based on data from
literature
Mortality for end-stage renal disease patients Age dependent Calculated based on data from
literature
Treatment parameters
Hazard ratio, sevelamer versus calcium carbonate 0.88 0–1 Jamal et al., 2013 [7]
Hazard ratio, CKD versus no CKD 1.83 0.915–2.745 Di Iorio et al. 2012 [6, 10]
Costs
Drug acquisition unit price
Sevelamer (S$/g) 1.41 0–4.23 SANOFI
Calcium carbonate (S$/g) 0.192 0.06–0.25 SANOFI
Usage dose
For non-dialysis CKD patients
Sevelamer (g/day) 2.184 Thompson et al. 2013 [8]
Calcium carbonate (g/day) 2.950 0–6 Thompson et al. 2013 [8]
For end-stage renal disease patients
Sevelamer (g/day)
Year 1 2.4 Assumed
Years 2–4 4.8 Assumed
Years 5–7 7.2 Assumed
Years 8–10 9.6 Assumed
Calcium carbonate (g/day) 2.95 0–6 Thompson et al. 2013 [8]
Hospitalization costs
Hospitalization cost per day (S$) 444 Singapore MOH
Length of hospitalization for dialysis patients with sevelamer (days) 12.3 5–20 St Peter et al. 2008 [19]
Length of hospitalization for dialysis patients with calcium carbonate (days) 13.9 5–20 St Peter et al. 2008 [19]
Length of pre-dialysis hospital stay for patients with sevelamer
(days per hospitalization)
5.8 Khan et al. 2002 [18]
Length of pre-dialysis hospital stay for patients with calcium
carbonate (days per hospitalization)
6.6 Khan et al. 2002 [18]
Annual risk of pre-dialysis hospitalization 0.58 Go et al. 2004 [17]
Dialysis costs
Haemodialysis cost (S$/month) 2517 Singapore MOH
Peritoneal dialysis costs (S$/month) 1670 Singapore MOH
Proportion of patients with haemodialysis dialysis in Singapore (%) 82.3 Singapore MOH
Total dialysis costs (per year) 28,400 14,200–42,600
Utilities
CKD patients not on dialysis 0.85 0.8–0.90 Gorodetskaya et al. 2005 [20]
End-stage renal disease patients 0.72 0.65–0.8 Gorodetskaya et al. 2005 [20]
All costs are in Singapore Dollars (S$)
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peritoneal and 82.3 % for haemodialysis), which were
extracted from the Singapore Renal Registry Annual
2013 Report [1].
Hospitalization costs in pre-dialysis and dialysis phases
were obtained by multiplying the non-subsidized
hospitalization cost per day (S$445) provided by
Singapore Ministry of Health [16] with the average num-
ber of hospitalized days per year for CKD patients and
ESRD patients, respectively. The average number of hos-
pitalized days per year for CKD patients was computed
by multiplying the annual risk of hospitalization for
CKD patients [17] with the average length of stay per
hospitalization (6.6 days and 5.8 days for calcium car-
bonate and sevelamer patients, respectively [18]). The
average number of hospitalized days per year for dialy-
sis patients were estimated in St Peter et al., i.e., 12.3
inpatient days for dialysis patients who were treated
with sevelamer versus 13.8 days for those on calcium
carbonate [19].
Health utility weights
Health utility weights were based on a time-trade-off
analysis from Gorodetskaya et al. Specifically, the health
utilities for a CKD patient undergoing or not undergoing
dialysis are 0.72 and 0.85, respectively [20].
Other model inputs
The age distribution of the cohort was defined to match
that from the Singapore Renal Registry Annual Report
2013 [1]. As age is a significant risk factor for mortality
of CKD patients, this real world age composition enables
the model to track the disease progression for patients
treated with sevelamer and calcium carbonate in
Singapore more accurately than the conventional ap-
proach of assuming all cohort members start at the same
age. Both future costs and utilities were discounted at
3.5 % as recommended by the UK NICE [21].
Sensitivity analysis
We supplemented the base case analysis with both
deterministic and probabilistic sensitivity analyses to
examine the robustness of the results. In the one-way
sensitivity analysis, we allowed each parameter to change
in a range that is based on the literature (e.g., for drug
dose) or is reasonably large (e.g., +/−50 % for hazard ra-
tio and dialysis costs and +/-100 % for drug costs). Re-
sults are presented in terms of a Tornado diagram, with
key variables shown in additional one way sensitivity
charts. We also conducted a sensitivity analysis using a
discount of 1.5 %.
In probabilistic sensitivity analysis, we assigned distri-
butions to all input parameters and performed 10,000
Monte Carlo simulations where each simulation gener-
ated an ICER. Results are presented graphically as cost
effectiveness acceptability curves which show the prob-
ability that each drug is cost-effective for any given cost-
effectiveness threshold. We assumed beta distributions for
all probabilities and utilities whose values were bounded
between 0 and 1, normal distributions for hazard ratios
and drug doses, and gamma distributions for medication
and dialysis costs (to capture its non-negative and skewed
features). The moments for these distributions were based
on the point estimates and on our choice of a relatively
large standard deviation (i.e., 25 % of the mean) [22].
Results
The age distribution of our simulated cohort is displayed
in Table 2. The average age of the cohort is 60, with pa-
tients aged between 50 and 70 accounting for more than
two-third of the cohort (i.e., 71 %). All cohort members
died after the model was run for 30 years.
The base case cost utility results are presented in
Table 3. Over a lifetime, a patient treated with sevelamer
costs more than a patient treated with calcium carbonate
(S$180,724 versus S$152,988) but also gains more QALYs
(6.34 versus 5.81). The ICER of sevelamer relative to cal-
cium carbonate is S$51,756 per QALY gained. Compared
with the NICE cost-effectiveness threshold of £30,000 or
S$61,000 per QALY (based on the £ SGD exchange rate
as of Nov. 24, 2012), sevelamer is cost effective compared
with calcium carbonate.
The Tornado diagram, displayed in Fig. 2, shows that
the ICER is most sensitive to changes in the prices of
sevelamer and dialysis. Figure 3 shows the ICER for
sevelamer as a function of its price. As expected, the
ICER increases as sevelamer becomes more expensive.
In particular, if the price of sevelamer exceeds S$1.69/g
(the intersection point between the ICER line and the
cost effectiveness threshold line), sevelamer is no lon-
ger cost effective. We also considered a high dose (i.e.,
three times the base-case dose) [23] and a low dose
(i.e., 50 % of the base-case dose) for calcium carbonate.
In both cases, sevelamer is still cost effective relative to
calcium carbonate with ICER being S$45,986/QALY
and S$53,198/QALY, respectively. Another sensitivity










Source: Singapore Renal Registry Annual Report 2013
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analysis indicates that sevelamer dominates calcium
carbonate (i.e., has lower cost and greater effectiveness)
when the time horizon is 6 years or less. Beyond six
years, sevelamer remains cost effective, although it be-
comes less attractive as the time horizon expands. The
reason for this is that, beyond six years, as the duration
on treatment increases, both dialysis and sevelamer
costs increase (and at the higher dosage) at a faster rate
than the increase in QALYs.
Figure 4 displays the cost effectiveness acceptability
curves for sevelamer and calcium carbonate derived
from the probabilistic sensitivity analysis around the
base case assumptions. If the willingness to pay (WTP)
per QALY gained is S$61,000 (i.e., the NICE threshold),
sevelamer is cost effective in 69 % of iterations.
Discussion
This study presents results of a cost utility analysis com-
paring sevelamer with calcium carbonate as alternative
treatments for hyperphosphatemia among CKD patients.
The model was updated with the best available data and
tailored for use in Singapore. Base case results suggest
that, using common thresholds for cost-effectiveness,
sevelamer is cost effective with an ICER of S$51,756 per
QALY gained. The results are robust to reasonable varia-
tions in a number of key parameters.
Thompson et al. generated an ICER of sevelamer rela-
tive to carbonate calcium of £23,878 (S$49,000) per
QALY gained [8]. Ironically, their slightly higher ICER is
due to use of a lower mortality hazard ratio (i.e., 0.45).
As shown in Fig. 5, sevelamer becomes less cost effective
as it becomes more effective at reducing mortality risks.
This is because a more effective sevelamer means that
more patients are on dialysis and for longer time pe-
riods. This increases dialysis and sevelamer costs (and at
higher dosages) at a greater rate than the increase in
QALYs, making sevelamer less cost effective. When
using the same hazard ratio as Thompson et al., our
ICER increases to S$52,477 per QALY, which is similar
to their estimate.
Ruggeri et al. found that sevelamer dominates calcium
carbonate (i.e., more effective and less expensive) when
assuming an optimistic mortality hazard ratio for sevela-
mer and a much shorter time horizon (i.e., three years)
[9]. When we apply their mortality hazard and a three-
year time horizon, our model generates an analogous re-
sult. The reason for the more favorable cost effectiveness
result in the short term is that when the time horizon is
short, most patients are in the no-dialysis state. Conse-
quently, a more effective sevelamer (i.e., lower mortality
hazard ratio) delays the onset and costs of dialysis, mak-
ing sevelamer more cost effective. In the longer term,
Table 3 Base case incremental cost utility results (lifetime
horizon)








152,988 0 5.81 0 0
Sevelamer 180,724 27,735.6 6.34 0.5359 51,756
All costs are in Singapore Dollars (S$). ICER incremental cost-effectiveness ratio.
Although our study cohort all starts out not requiring dialysis, a large majority
of them progress to end-stage renal disease and require dialysis by the end of
the model simulation
Fig. 2 Tornado diagram
Nguyen et al. BMC Nephrology  (2016) 17:45 Page 6 of 9
patients transition to dialysis, which results in much
higher costs and a lower cost-effectiveness ratio.
Our study has a number of limitations. The first limi-
tation, given our focus on Singapore, is the lack of
Singapore specific data for a number of model inputs.
With the exception of costs, the base case age distribu-
tion and the mortality hazard ratio, other parameters
were not specific to Singapore. In particular, we assumed
the health utilities for CKD patients do not differ be-
tween Caucasians and Singaporeans. Given access to
treatment is similar in the US (where the study was con-
ducted) and Singapore, we see no reason to believe that
this assumption would not hold. Moreover, we allowed
this and other key variables to change in a reasonably
large range in the sensitivity analyses, and the primary
conclusion remains unchanged.
Another limitation is that we assumed the mortality
risks for the CKD subgroups could be estimated solely
with information on overall mortality rates, mortality
hazard rates for CKD patients and rates for sevelamer-
Fig. 3 One-way sensitivity analysis (price of sevelamer)
Fig. 4 Cost-effectiveness acceptability curve
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treated CKD patients. In reality, these calculations should
be based on both hazard rates and the prevalence of each
subgroup in the population. However, no data on age-
specific prevalence for CKD patients (regardless of treat-
ment regimen) is available for Singapore. Consequently,
our calculation of CKD mortality risks did not use the
prevalence of the CKD subgroup. In doing so, we essen-
tially assumed that the mortality risks for the general popu-
lation are equal to the mortality risks for the non-CKD
population. However, because CKD patients represent a
small fraction of the total population, this should have a
negligible effect on the overall and sevelamer specific CKD
mortality rates and therefore on the estimated ICERs.
A further limitation of the paper is that it compared the
outcomes of sevelamer to calcium carbonate. In certain
countries, such as the United States only calcium acetate
is approved for non-dialysis CKD patients. However, in
other countries such as Singapore, there is currently no
such restriction. Furthermore, the most recent meta-
analysis on the topic by Jamal et al., which was one of the
data sources for our study, grouped calcium carbonate
and calcium acetate into one category. Finally, our analysis
only modelled the scenario where a patient received one
phosphate binder. In clinical practice some patients may
require multiple binders for adequate phosphorus control.
Conclusions
From a third party payer perspective and considering a
lifetime time horizon, sevelamer is likely to be cost ef-
fective relative to calcium carbonate as a treatment for
hyperphosphatemia in CKD patients in Singapore and in
countries with similar health systems.




Availability of data and materials
Source for data used in the analysis has been provided in
Additional file 1: Table S1.
Appendix
Additional file
Additional file 1: CHEERS checklist—Items to include when reporting
economic evaluations of health interventions. (DOCX 19 kb)
Abbreviations
CKD: chronic kidney disease; CVD: cardiovascular disease; ICER: incremental cost
effectiveness ratio; NICE: National Institute for Health and Care Excellence;
QALY: quality adjusted life years; WTP: willingness-to-pay.
Fig. 5 Relationship between incremental cost-effectiveness ration and hazard ratio for sevelamer
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176,851 0 6.40 0 0
Sevelamer 212,103 35,252 7.05 0.65 53,848
All costs are in Singapore Dollars (S$). ICER incremental cost-effectiveness ratio.
Although our study cohort all starts out not requiring dialysis, a large majority
of them progress to end-stage renal disease and require dialysis by the end of
the model simulation
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